|
TGFBR1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
5.9340999999935E-05 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
1.63979940737136E-12 |
| Stage1-vs-Stage2 |
2.198400E-01 |
| Stage1-vs-Stage3 |
7.528000E-01 |
| Stage1-vs-Stage4 |
3.417600E-01 |
| Stage2-vs-Stage3 |
1.611190E-01 |
| Stage2-vs-Stage4 |
5.427800E-01 |
| Stage3-vs-Stage4 |
2.662200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.09590000000071E-05 |
| Normal-vs-Asian |
5.84330361874663E-11 |
| Caucasian-vs-AfricanAmerican |
6.366000E-01 |
| Caucasian-vs-Asian |
3.302200E-01 |
| AfricanAmerican-vs-Asian |
3.796400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62436730732907E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.890400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.82890369515576E-11 |
| Normal-vs-Age(81-100Yrs) |
4.701500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.200200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.539190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.106830E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.145600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.404600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.348000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.393400E-01 |
| Classical-VS-Follicular |
2.51088039249225E-12 |
| Classical-VS-Other |
3.853000E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
1.60330000387177E-08 |
| Tall-VS-Other |
3.337400E-01 |
| Tall-VS-Normal |
2.22855067733008E-12 |
| Follicular-VS-Other |
3.699000E-01 |
| Follicular-VS-Normal |
5.567100E-04 |
| Other-VS-Normal |
1.396580E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
1.14850018384516E-10 |
| N0-vs-N1 |
4.768800E-01 |
|
|
